Lakewood-Amedex Biotherapeutics
CompanyUnited States
Lakewood-Amedex Biotherapeutics develops one asset, preclinical (Nu-8 in pulmonary infection). Mostly small molecule; based in the United States.
- 1
- Asset
- Furthest stage
- Preclinical
- 0
- Trials
- 0
- Signals
Pipeline
1Bisphosphocin antimicrobial compound inhibiting bacterial growth
Preclinical, Small molecule, pulmonary infection, urinary tract infection
Full company profiles: pipeline, trials, funding and people.